<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lepirudin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00001</strong>&#160; (BIOD00024, BTD00024)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00001.png?1266600387"><img alt="Db00001" src="/system/protein_structures/thumb/DB00001.png?1266600387"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>287</sub>H<sub>440</sub>N<sub>80</sub>O<sub>110</sub>S<sub>6</sub></td></tr><tr><th>Protein average weight</th><td>6963.4250</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;DB00001 sequence
LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP
EEYLQ</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00001/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Hirudin variant-1</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Refludan</td><td>Berlex Labs</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antithrombins">Antithrombins</a></li>
<li><a href="/mesh/fibrinolytic-agents">Fibrinolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>120993-53-5</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of heparin-induced thrombocytopenia</td></tr><tr><th>Pharmacodynamics</th><td>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</td></tr><tr><th>Mechanism of action</th><td>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </td></tr><tr><th>Absorption</th><td>Bioavailability is 100% following injection.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>12.2 L [Healthy young subjects (n = 18, age 18-60 years)]</li>
	<li>18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]</li>
	<li>18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]</li>
	<li>32.1 L [<span class="caps">HIT</span> patients (n = 73)]</li>
</ul></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</p></td></tr><tr><th>Route of elimination</th><td>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</td></tr><tr><th>Half life</th><td>Approximately 1.3 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>164 ml/min [Healthy 18-60 yrs]</li>
	<li>139 ml/min [Healthy 65-80 yrs]</li>
	<li>61 ml/min [renal impaired]</li>
	<li>114 ml/min [<span class="caps">HIT</span> (Heparin-induced thrombocytopenia)]</li>
</ul></td></tr><tr><th>Toxicity</th><td>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Lepirudin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00278?highlight%5Bcompounds%5D%5B%5D=DB00001&amp;highlight%5Bproteins%5D%5B%5D=DB00001">SMP00278</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bayer healthcare pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bayerhealthcare.com">Bayer Healthcare</a></li>
<li><a href="http://www.berlex.com">Berlex Labs</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Refludan 50 mg vial</td><td>273.19USD</td><td>vial</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5180668</td><td>1993-01-19</td><td>2010-01-19</td></tr><tr><td>Canada</td><td>1339104</td><td>1997-07-29</td><td>2014-07-29</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>65 &#176;C</td><td>Otto, A. &amp; Seckler, R. Eur. J. Biochem. 202:67-73 (1991)</td></tr><tr><td>hydrophobicity</td><td>-0.777</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>isoelectric point</td><td>4.04</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16244762">Pubmed</a></li>
	<li>Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16690967">Pubmed</a></li>
	<li>Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia &#8211; results of the third prospective study (<span class="caps">HAT</span>-3) and a combined analysis of <span class="caps">HAT</span>-1, <span class="caps">HAT</span>-2, and <span class="caps">HAT</span>-3. J Thromb Haemost. 2005 Nov;3(11):2428-36. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16241940">Pubmed</a></li>
	<li>Askari AT, Lincoff AM: Antithrombotic Drug Therapy in Cardiovascular Disease. 2009 Oct; pp. 440&#8211;. <span class="caps">ISBN</span> 9781603272346. <a href="http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440">Google books</a>.</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P01050" target="_blank">P01050 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450195" target="_blank">PA450195 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2240996" target="_blank">2240996 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/lepirudin.htm" target="_blank">http://www.rxlist.com/cgi/generic/lepirudin.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/lepirudin.html" target="_blank">http://www.drugs.com/cdi/lepirudin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Lepirudin" target="_blank">Lepirudin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>B01AE02<ul class="atc-drug-tree"><li><a href="/atc/B#B">B &#8212; BLOOD AND BLOOD FORMING ORGANS</a></li><li><a href="/atc/B01#B01">B01 &#8212; ANTITHROMBOTIC AGENTS</a></li><li><a href="/atc/B01A#B01A">B01A &#8212; ANTITHROMBOTIC AGENTS</a></li><li><a href="/atc/B01AE#B01AE">B01AE &#8212; Direct thrombin inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>20:12.04.12</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=4HIR" target="_blank">4HIR <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00001.pdf?1265924858">show</a>(128 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00001.pdf?1368416245">show</a>(567 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>